Document is current
Any future updates will be listed below
-
Authors
Abuhelwa, Ziad
Alloghbi, Abdurahman
Alqahtani, Ali
Nagasaka, Misako https://orcid.org/0000-0001-5308-615X
- License Information
-
More Information
Article History
Accepted: 23 May 2022
First Online: 27 June 2022
Declarations
:
: No external funding was received for the preparation of this article.
: MN is on the advisory board for AstraZeneca, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Janssen, Pfizer, Eli Lilly and Company, and Genentech; is a consultant for Caris Life Sciences (virtual tumor board); a speaker for Blueprint Medicines and Takeda; and reports travel support from AnHeart Therapeutics. All other authors have no conflicts of interest that are directly relevant to the contents of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Z. Abuhelwa, A. Allghbi, A. Alqahtani and M. Nagasaka all contributed to the writing and revision of the manuscript.
